Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The prognostic and therapeutic implications of MRD in AML

Nicholas Short • 29 Sep 2022
SOHO 2022
Acute Myeloid Leukemia Leukemia

Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the important prognostic and therapeutic implications of measurable residual disease (MRD) in acute myeloid leukemia (AML). Dr Short first discusses the various markers that are used in MRD monitoring, and then goes on to highlight the value of using MRD status when making therapeutic decisions. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicholas Short

2:50
The impact of induction therapy on post-transplant outcomes in AML
Nicholas Short • 6 Sep 2023
2:20
Pevonedistat, azacitidine and venetoclax triplet therapy for AML, MDS and CMML
Nicholas Short • 6 Sep 2023
2:30
The importance of MRD-guided therapy in ALL
Nicholas Short • 6 Sep 2023
2:40
The role of PCR and NGS-based MRD in Ph+ ALL
Nicholas Short • 6 Sep 2023

Related Videos

8:40
Investigating PP2A-based therapeutic strategies for KMT2A-rearranged acute leukemia
Maria Teresa Esposito • 25 Apr 2024
1:55
Factors to consider when choosing a treatment option for patients with CLL
Piers Patten • 28 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals